Indication
Low Grade Astrocytoma
3 clinical trials
3 products
2 drugs
Clinical trial
A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination With Vinblastine for Non-NF1, Non-TSC Patients With Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 MutationsStatus: Recruiting, Estimated PCD: 2026-12-30
Product
SelumetinibProduct
VinblastineClinical trial
Phase II Study of Antineoplastons A10 and AS2-1 in Children With Low Grade AstrocytomaStatus: Completed, Estimated PCD: 2004-07-01
Product
Antineoplaston therapyClinical trial
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)Status: Recruiting, Estimated PCD: 2026-12-31
Drug
AN0025Drug
Vincristine